[Drug therapy of hemorrhagic syndromes. Part I].
D000818:Animals; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D003029:Coagulants / Q000009:adverse effects / Q000627:therapeutic use*; D005419:Flavonoids / Q000627:therapeutic use*; D006470:Hemorrhage / Q000188:drug therapy*; D006474:Hemorrhagic Disorders / Q000188:drug therapy; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D011693:Purpura / Q000188:drug therapy*; D012910:Snake Venoms / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*; D014812:Vitamin K / Q000009:adverse effects / Q000627:therapeutic use
D000933:Antifibrinolytic Agents; D003029:Coagulants; D005419:Flavonoids; D006490:Hemostatics; D012910:Snake Venoms; D014688:Venoms; D014812:Vitamin K
Terapia farmacologica delle sindromi emorragiche. Parte I